June Agenda

Improving the Lives of Patients with Depression

This educational activity will provide clinicians an evidence-based update on diagnosing and treating treatment-resistant depression (TRD) and anhedonia, two the most challenging aspects pertaining to depression. The activity will review best practices for diagnosing TRD, evaluate effective pharmacological and non-pharmacological treatment strategies for TRD, and discuss practical implementation. Participants will be able to optimize diagnosis and management of TRD and anhedonia to improve quality of life for patients with difficult to treat depression.

All sessions will be held in Pacific Time (PT).

Saturday, June 29, 2024

7:00 am - 8:00 am

Resistance is Futile: Guidelines for Treatment-Resistant Depression

Roger S. McIntyre, MD, FRCPC

Treatment-resistant depression (TRD), perhaps more suitably referred to as “difficult to treat depression”, has historically been difficult to define, let alone identify and treat effectively. In this presentation, Dr. Roger McIntyre provides an update on the state-of-the-science when it comes to diagnosing TRD as well as the guidance for utilizing the variety of available and emerging treatment options that have shown efficacy in patients with TRD.

8:00 am - 9:00 am

Industry Session^†

Sponsored by Intra-Cellular Therapies, Inc.

9:00 am – 9:05 am

Break

9:05 am – 9:35 am

Poster Session^†

TBD

9:35 am - 10:35 am

Turn That Frown Upside Down: Evidence-based Update on Anhedonia

Vladimir Maletic, MD, MS

There is increasing recognition that the presence of anhedonia, which encompasses a deficit in the ability to feel and/or anticipate pleasure, has a tremendous impact on outcomes (including the worst possible outcome, suicide) and quality of life for patients with depression. Here, Dr. Vladimir Maletic will explore the aberrant neurocircuitry hypothesized to underlie anhedonia as well as available and emerging treatments that may reduce anhedonia by targeting and correcting faulty circuits involved in salience and reward.

10:35 am - 11:00 am

Live Panel Q&A

Vladimir Maletic, MD, MS and Roger S. McIntyre, MD, FRCPC

^†The content of all non-CME/CE events (Industry Symposia, Disease State Sessions, and Poster Sessions) and the views expressed therein are those of the presenting entity and not of NEI. These events are not part of the scientific program and do not provide CME/CE credit. By opening a non-CME/CE event, the attendee opts in to receive follow-up information from the commercial sponsor.

Program Faculty

Vladimir Maletic, MD, MS

Clinical Professor, Department of Psychiatry and Behavioral Science, University of South Carolina School of Medicine Greenville, SC

Dr. Vladimir Maletic is a clinical professor of psychiatry and behavioral science at the University of South Carolina School of Medicine in Greenville, and a consulting associate in the Division of Child and Adolescent Psychiatry, Department of Psychiatry, at Duke University in Durham, North Carolina. Dr. Maletic received his medical degree in 1981 and his master’s degree in neurobiology in 1985, both from the University of Belgrade in Yugoslavia. He went on to complete a residency in psychiatry at the Medical College of Wisconsin in Milwaukee, followed by a residency in child and adolescent psychiatry at Duke University. 

Dr. Maletic is a member of several professional organizations, including the Southern Psychiatric Association and The American College of Psychiatrists. He has published three books, including “The New Mind-Body Science of Depression”, numerous articles and several book chapters. Dr. Maletic has participated in various national and international meetings and congresses. His special areas of interest include the neurobiology of mood disorders, schizophrenia, pain, and the regulation of sleep and wakefulness. Dr. Maletic is board certified in psychiatry and neurology.

Roger S. McIntyre, MD, FRCPC

Professor, Departments of Psychiatry and of Pharmacology, University of Toronto, Toronto, ON, Canada 

Chairman and Executive Director, Brain and Cognition Discovery Foundation, Toronto, ON, Canada 

Director and Chair, Scientific Advisory Board, Depression and Bipolar Support Alliance, Chicago, IL, USA 

Clinical Professor, State University of New York Upstate Medical University, Syracuse, NY, USA 

Clinical Professor, Department of Psychiatry and Neurosciences, University of California School of Medicine, Riverside, CA, USA 

Professor and Nanshan Scholar, Guangzhou Medical University, Guangzhou, China 

Adjunct Professor, College of Medicine, Korea University, Seoul, South Korea 

Visiting Professor, College of Medicine, University of the Philippines, Manila, Philippines 

Roger S. McIntyre, MD, FRCPC, is currently a Professor of Psychiatry and Pharmacology at the University of Toronto and Head of the Mood Disorders Psychopharmacology Unit at the University Health Network, Toronto, Canada. Dr. McIntyre is also Executive Director of the Brain and Cognition Discovery Foundation in Toronto, Canada.  

Dr. McIntyre was named by Thomson Reuters in 2014 and 2015, as one of “The World’s Most Influential Scientific Minds”. This distinction is given by publishing the largest number of articles that rank among those most frequently cited by researchers globally in 21 broad fields of science and social science during the previous decade.     

Dr. McIntyre is involved in multiple research endeavors which primarily aim to characterize the association between mood disorders, notably cognitive function, and medical comorbidity. His works broadly aims to characterize the underlying causes of cognitive impairment in individuals with mood disorders and their impact on workplace functioning. This body of work has provided a platform for identifying novel molecular targets to treat and prevent mood disorders and accompanying cognitive impairment.  

Dr. McIntyre is extensively involved in medical education. He is a highly sought-after speaker at both national and international meetings. He has received several teaching awards from the University of Toronto, Department of Psychiatry and has been a recipient of the joint Canadian Psychiatric Association (CPA) / Council of Psychiatric Continuing Education Award for the Most Outstanding Continuing Education Activity in Psychiatry in Canada. 

Dr. McIntyre is a contributor to the “Florida Medicaid Drug Therapy Management Program for Behavioral Health: Guidelines for the treatment of adults with Major Depressive Disorder and Bipolar Disorder”. Dr. McIntyre is also the co-chair of the Canadian Network for Mood and Anxiety Treatments (CANMAT) Task Force on the Treatment of Comorbidity in Adults with Major Depressive Disorder or Bipolar Disorder and as well a contributor to the “CANMAT Guidelines for the Treatment of Depressive Disorders and Bipolar Disorders”. Dr. McIntyre has published hundreds of peer-reviewed articles and has edited and/or co-edited several textbooks on mood disorders. 

Dr. McIntyre completed his medical degree at Dalhousie University. He received his Psychiatry residency training and Fellowship in Psychiatric Pharmacology at the University of Toronto. 